FDA Speeds Up Baby Tests for Rare Genetic Disorders
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the lysosomal storage disorder newborn screening test system into a special safety category called Class II. This means the test will have clear safety rules, making it easier and safer for babies to get screened early. This change helps companies bring these important tests to hospitals faster without extra red tape, so families get quicker access to life-saving info.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Newborn Test Put Under Safety Rules
The FDA has classified the lysosomal storage disorder newborn screening test system as Class II (special controls). This means the test will have clear safety rules, and the FDA says that classification provides a reasonable assurance of the device's safety and effectiveness.
Faster Hospital Access To Newborn Tests
The FDA says classifying the test as Class II (special controls) will reduce regulatory burdens and enhance patients' access to beneficial innovative devices. That could help companies bring lysosomal storage disorder newborn screening tests to hospitals faster, giving families quicker access to life-saving information about their babies.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-11780, Protection of Stratospheric Ozone; CFR Correction
The EPA fixed some technical details in the rules about safe refrigerants that protect our ozone layer. This update adds important footnotes explaining safety and design standards for vehicle air conditioners, making sure everyone uses the right stuff the right way. If you work with refrigerants, these clarifications help keep things clear and safe—no new costs or deadlines, just better info!
Next: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation
The FDA is officially putting the cream used to block x-rays into a special safety category called Class II. This means the cream will have clear rules to keep it safe and effective, making it easier for patients to get new and helpful products. This change helps companies by cutting some red tape without costing extra time or money.